Lilly’s new product was approved by the ... Both products are priced at a similar level to the glucagon injection kits available on the market, with a list price of $280 per dose, and in the ...

The portfolio includes top brands like Prega News (pregnancy test kit), Manforce (condoms), Unwanted ... is co-developed by Innovent and Eli Lilly. Sintilimab is expected to be launched in the ...

US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering. France-based NEOSYAD recently gained CE marking under the European Union’s ...

The format is potentially more convenient than traditional glucagon kits from the likes of Fresenius Kabi and Amphastar, but Xeris has struggled to penetrate the vast opportunity. Xeris said it ...

Both companies are competing in GLP-1 (Glucagon-like Peptide-1) receptor agonists that help in promoting weight loss. BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk ...

Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy) produced by Novo Nordisk A/S (NYSE: NVO) and tirzepatide (Mounjaro and Zepbound) produced by Eli Lilly and Co. (NYSE ...

Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that ...